ClinicalTrials.gg
CompletedNCT06264453Updated Mar 14, 2025

A Study to Evaluate the Efficacy and Safety of KH001 in Patients with Dentin Hypersensitivity

A Phase 2 interventional study of KH001 and Placebo in Dentin Hypersensitivity, sponsored by HysensBio Co., Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-03-14.

Sponsored by HysensBio Co., Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
171
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of KH001 in patients with dentin hypersensitivity.

Read the detailed description

This study is multicenter, double-blind, placebo-controlled, randomized, parallel-designed, phase 2 study to evaluate the efficacy and safety of KH001. The total duration of the study will be approximately 7 to 11 weeks. Clinical safety evaluations will include physical examinations, vital signs, clinical laboratory results, and Adverse Event monitoring.

02

Conditions studied

  • Dentin Hypersensitivity

Browse trials for

Keywords

  • Dentin Sensitivity
  • Denin Hypersensitivity
03

In context

Dentin Sensitivity

290 studies on the registry are indexed under Dentin Sensitivity; 47 are open to participants now.

This study's enrollment of 171 is above the median of 60 across 280 interventional studies indexed under Dentin Sensitivity.

Browse Dentin Sensitivity studies →

Lead sponsor

HysensBio Co., Ltd is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least 19 years old by the time of the screening visit
  • Be in good general health as determined by the investigator
  • Have at least 2 non-adjacent teeth and is diagnosed with hypersensitive

Exclusion criteria

Exclusion Criteria:

  • Is allergic to the active drug substance or other used in the product
  • Has any history of alcohol or drug abuse
  • Has received any treatment related to dentin within 8 weeks prior to the screening visit
  • Has active dental caries or history of dental caries
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
171 participants (actual)

Study arms

  • Experimental
    Group A

    KH001 0.2mg/mL

    Drug: KH001

  • Experimental
    Group B

    KH001 0.4mg/mL

    Drug: KH001

  • Placebo comparator
    Group C

    Water for Injection

    Drug: Placebo

Interventions

  • DrugKH001

    topical applications of KH001

  • DrugPlacebo

    topical applications of Water for Injection

06

What researchers measure

Primary outcomes

  1. Change from baseline in Schiff sensitivity score

    Schiff sensitivity score 0-3 by air blast

    Time frame: Baseline and Day 36

Secondary outcomes

  1. Change from baseline in a Schiff sensitivity score

    Schiff sensitivity score 0-3 by an evaporative air

    Time frame: Baseline, Day 8, 15, 22 and 43

  2. Change from baseline in a Tactile threshold

    Tactile threshold by yeaple probe

    Time frame: Baseline, Day 8, 15, 22, 36 and 43

  3. Change from baseline in Visual Analogue Scale

    100mm Visual Analogue Scale

    Time frame: Baseline, Day 8, 15, 22, 36 and 43

07

Study locations

1 site
  • Kyung Hee University Dental Hospital
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Sep 2024, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2024
First posted
Feb 20, 2024
StartActual
Mar 19, 2024
Primary completionActual
Sep 25, 2024
CompletionActual
Sep 25, 2024
Last update
Mar 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06264453
Lead sponsor
HysensBio Co., Ltd
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Mar 19, 2024
Primary completion
Sep 25, 2024
Completion
Sep 25, 2024
Last update
Mar 14, 2025

Study contacts

Kyoung-Kyu Choi, D.D.S
principal investigator · Kyung Hee University Dentistry Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KH001

Start the discussion